检索结果 - Meade, Angela

Randomized controlled pilot trial of naloxone‐on‐release to prevent post‐prison opioid overdose deaths 由 Parmar, Mahesh K. B., Strang, John, Choo, Louise, Meade, Angela M., Bird, Sheila M.

获取全文 获取全文 获取全文

Adding new experimental arms to randomised clinical trials: Impact on error rates 由 Choodari-Oskooei, Babak, Bratton, Daniel J, Gannon, Melissa R, Meade, Angela M, Sydes, Matthew R, Parmar, Mahesh KB

获取全文 获取全文 获取全文

External data required timely response by the Trial Steering-Data Monitoring Committee for the NALoxone InVEstigation (N-ALIVE) pilot trial 由 Bird, Sheila M., Strang, John, Ashby, Deborah, Podmore, John, Robertson, J. Roy, Welch, Sarah, Meade, Angela M., Parmar, Mahesh K.B.

获取全文 获取全文 获取全文

Methods for delivering the UK's multi‐centre prison‐based naloxone‐on‐release pilot randomised trial (N‐ALIVE): Europe's largest prison‐based randomised controlled trial... 由 Meade, Angela Mary, Bird, Sheila Macdonald, Strang, John, Pepple, Tracey, Nichols, Laura Lea, Mascarenhas, Monica, Choo, Louise, Parmar, Mahesh Kumar Bhikhubhai

获取全文 获取全文 获取全文

Intermittent chemotherapy plus either intermittent or continuous cetuximab for first-line treatment of patients with KRAS wild-type advanced colorectal cancer (COIN-B): a randomise... 由 Wasan, Harpreet, Meade, Angela M, Adams, Richard, Wilson, Richard, Pugh, Cheryl, Fisher, David, Sydes, Benjamin, Madi, Ayman, Sizer, Bruce, Lowdell, Charles, Middleton, Gary, Butler, Rachel, Kaplan, Richard, Maughan, Tim

获取全文 获取全文 获取全文

What Survival Benefits are Needed to Make Adjuvant Sorafenib Worthwhile After Resection of Intermediate- or High-Risk Renal Cell Carcinoma? Clinical Investigators’ Preferences in t... 由 Lawrence, Nicola J., Martin, Andrew, Davis, Ian D., Troon, Simon, Sengupta, Shomik, Hovey, Elizabeth, Coskinas, Xanthi, Kaplan, Richard, Smith, Benjamin, Ritchie, Alastair, Meade, Angela, Eisen, Tim, Blinman, Prunella, Stockler, Martin R.

获取全文 获取全文 获取全文

Somatic profiling of the epidermal growth factor receptor pathway in tumours from patients with advanced colorectal cancer, treated with chemotherapy ± cetuximab 由 Smith, Christopher G., Fisher, David, Claes, Bart, Maughan, Timothy S., Idziaszczyk, Shelley, Peuteman, Gilian, Harris, Rebecca, James, Michelle D., Meade, Angela, Jasani, Bharat, Adams, Richard A., Kenny, Sarah, Kaplan, Richard, Lambrechts, Diether, Cheadle, Jeremy P.

获取全文 获取全文 获取全文

Analyses of 7,635 patients with colorectal cancer using independent training and validation cohorts show that rs9929218 in CDH1 is a prognostic marker of survival 由 Smith, Christopher G., Fisher, David, Harris, Rebecca, Maughan, Timothy S., Phipps, Amanda I., Richman, Susan, Seymour, Matthew, Tomlinson, Ian, Rosmarin, Dan, Kerr, David, Chan, Andrew T., Peters, Ulrike, Newcomb, Polly A., Idziaszczyk, Shelley, West, Hannah, Meade, Angela, Kaplan, Richard, Cheadle, Jeremy P.

获取全文 获取全文 获取全文

Intermittent versus continuous oxaliplatin and fluoropyrimidine combination chemotherapy for first-line treatment of advanced colorectal cancer: results of the randomised phase 3 M... 由 Adams, Richard A, Meade, Angela M, Seymour, Matthew T, Wilson, Richard H, Madi, Ayman, Fisher, David, Kenny, Sarah L, Kay, Edward, Hodgkinson, Elizabeth, Pope, Malcolm, Rogers, Penny, Wasan, Harpreet, Falk, Stephen, Gollins, Simon, Hickish, Tamas, Bessell, Eric M, Propper, David, Kennedy, M John, Kaplan, Richard, Maughan, Timothy S

获取全文 获取全文 获取全文

External Validation of the 2003 Leibovich Prognostic Score in Patients Randomly Assigned to SORCE, an International Phase III Trial of Adjuvant Sorafenib in Renal Cell Cancer 由 Oza, Bhavna, Eisen, Tim, Frangou, Eleni, Stewart, Grant D., Bex, Axel, Ritchie, Alastair W.S., Kaplan, Rick, Smith, Benjamin, Davis, Ian D., Stockler, Martin R., Albiges, Laurence, Escudier, Bernard, Larkin, James, Joniau, Steven, Hancock, Barry, Hermann, Gregers G., Bellmunt, Joaquim, Parmar, Mahesh K.B., Royston, Patrick, Meade, Angela

获取全文 获取全文 获取全文

Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial 由 Maughan, Timothy S, Adams, Richard A, Smith, Christopher G, Meade, Angela M, Seymour, Matthew T, Wilson, Richard H, Idziaszczyk, Shelley, Harris, Rebecca, Fisher, David, Kenny, Sarah L, Kay, Edward, Mitchell, Jenna K, Madi, Ayman, Jasani, Bharat, James, Michelle D, Bridgewater, John, Kennedy, M John, Claes, Bart, Lambrechts, Diether, Kaplan, Richard, Cheadle, Jeremy P

获取全文 获取全文 获取全文

Common Variation at 1q24.1 (ALDH9A1) Is a Potential Risk Factor for Renal Cancer 由 Henrion, Marc Y. R., Purdue, Mark P., Scelo, Ghislaine, Broderick, Peter, Frampton, Matthew, Ritchie, Alastair, Meade, Angela, Li, Peng, McKay, James, Johansson, Mattias, Lathrop, Mark, Larkin, James, Rothman, Nathaniel, Wang, Zhaoming, Chow, Wong-Ho, Stevens, Victoria L., Diver, W. Ryan, Albanes, Demetrius, Virtamo, Jarmo, Brennan, Paul, Eisen, Timothy, Chanock, Stephen, Houlston, Richard S.

获取全文 获取全文 获取全文

Common variation at 2q22.3 (ZEB2) influences the risk of renal cancer 由 Henrion, Marc, Frampton, Matthew, Scelo, Ghislaine, Purdue, Mark, Ye, Yuanqing, Broderick, Peter, Ritchie, Alastair, Kaplan, Richard, Meade, Angela, McKay, James, Johansson, Mattias, Lathrop, Mark, Larkin, James, Rothman, Nathaniel, Wang, Zhaoming, Chow, Wong-Ho, Stevens, Victoria L., Ryan Diver, W., Gapstur, Susan M., Albanes, Demetrius, Virtamo, Jarmo, Wu, Xifeng, Brennan, Paul, Chanock, Stephen, Eisen, Timothy, Houlston, Richard S.

获取全文 获取全文 获取全文

Adjuvant Sorafenib for Renal Cell Carcinoma at Intermediate or High Risk of Relapse: Results From the SORCE Randomized Phase III Intergroup Trial 由 Eisen, Tim, Frangou, Eleni, Oza, Bhavna, Ritchie, Alastair W.S., Smith, Benjamin, Kaplan, Rick, Davis, Ian D., Stockler, Martin R., Albiges, Laurence, Escudier, Bernard, Larkin, James, Bex, Axel, Joniau, Steven, Hancock, Barry, Hermann, Gregers G., Bellmunt, Joaquim, Hodgkinson, Elizabeth, Stewart, Grant D., Barber, Jim, Brown, Janet, McMenemin, Rhona, Nathan, Paul, Pickering, Lisa M., Parmar, Mahesh K.B., Meade, Angela

获取全文 获取全文 获取全文

Image-based consensus molecular subtype (imCMS) classification of colorectal cancer using deep learning 由 Sirinukunwattana, Korsuk, Domingo, Enric, Richman, Susan D, Redmond, Keara L, Blake, Andrew, Verrill, Clare, Leedham, Simon J, Chatzipli, Aikaterini, Hardy, Claire, Whalley, Celina M, Wu, Chieh-hsi, Beggs, Andrew D, McDermott, Ultan, Dunne, Philip D, Meade, Angela, Walker, Steven M, Murray, Graeme I, Samuel, Leslie, Seymour, Matthew, Tomlinson, Ian, Quirke, Phil, Maughan, Timothy, Rittscher, Jens, Koelzer, Viktor H

获取全文 获取全文 获取全文

RAMPART: A model for a regulatory-ready academic-led phase III trial in the adjuvant renal cell carcinoma setting 由 Meade, Angela, Oza, Bhavna, Frangou, Eleni, Smith, Ben, Bryant, Hanna, Kaplan, Rick, Choodari-Oskooei, Babak, Powles, Tom, Stewart, Grant D., Albiges, Laurence, Bex, Axel, Choueiri, Toni K., Davis, Ian D., Eisen, Tim, Fielding, Alison, Harrison, David J., McWhirter, Anita, Mulhere, Salena, Nathan, Paul, Rini, Brian, Ritchie, Alastair, Scovell, Sarah, Shakeshaft, Clare, Stockler, Martin R., Thorogood, Nat, Larkin, James, Parmar, Mahesh K.B.

获取全文 获取全文 获取全文

RAMPART: A phase III multi-arm multi-stage trial of adjuvant checkpoint inhibitors in patients with resected primary renal cell carcinoma (RCC) at high or intermediate risk of rela... 由 Oza, Bhavna, Frangou, Eleni, Smith, Ben, Bryant, Hanna, Kaplan, Rick, Choodari-Oskooei, Babak, Powles, Tom, Stewart, Grant D., Albiges, Laurence, Bex, Axel, Choueiri, Toni K., Davis, Ian D., Eisen, Tim, Fielding, Alison, Harrison, David, McWhirter, Anita, Mulhere, Salena, Nathan, Paul, Rini, Brian, Ritchie, Alastair, Scovell, Sarah, Shakeshaft, Clare, Stockler, Martin R., Thorogood, Nat, Parmar, Mahesh K.B., Larkin, James, Meade, Angela

获取全文 获取全文 获取全文